Plus Therapeutics, Inc.
PSTV
$0.5725
-$0.0554-8.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.39M | 1.06M | 1.41M | 1.46M | 1.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.39M | 1.06M | 1.41M | 1.46M | 1.28M |
| Cost of Revenue | 1.25M | 1.76M | 2.19M | 2.86M | 2.77M |
| Gross Profit | 144.00K | -697.00K | -774.00K | -1.40M | -1.49M |
| SG&A Expenses | 1.68M | 2.84M | 3.13M | 2.40M | 2.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.93M | 4.60M | 5.31M | 5.26M | 4.98M |
| Operating Income | -1.54M | -3.54M | -3.90M | -3.80M | -3.70M |
| Income Before Tax | 5.15M | -17.40M | -3.90M | -2.87M | -2.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.15M | -17.40M | -3.90M | -2.87M | -2.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.15M | -17.40M | -3.90M | -2.87M | -2.94M |
| EBIT | -1.54M | -3.54M | -3.90M | -3.80M | -3.70M |
| EBITDA | -1.46M | -3.39M | -3.70M | -3.60M | -3.53M |
| EPS Basic | 0.11 | -1.19 | -0.50 | -0.37 | -0.45 |
| Normalized Basic EPS | 0.07 | -0.75 | -0.31 | -0.23 | -0.28 |
| EPS Diluted | -0.01 | -1.19 | -0.50 | -0.37 | -0.71 |
| Normalized Diluted EPS | 0.02 | -0.75 | -0.31 | -0.23 | -0.17 |
| Average Basic Shares Outstanding | 48.39M | 14.57M | 7.86M | 7.86M | 6.50M |
| Average Diluted Shares Outstanding | 209.16M | 14.57M | 7.86M | 7.86M | 10.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |